<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="855">
  <stage>Registered</stage>
  <submitdate>25/10/2005</submitdate>
  <approvaldate>25/11/2005</approvaldate>
  <actrnumber>ACTRN12605000764639</actrnumber>
  <trial_identification>
    <studytitle>The pharmacokinetics of plasma-derived Factor XIII in children</studytitle>
    <scientifictitle>The pharmacokinetics of plasma-derived Factor XIII in children with congential Factor XIII Deficiency.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Congenital Factor XIII deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To assess the pharmacokinetics in children following their "usual" dose of plasma-derived Factor XIII (Fibrogammin P).
Will only be performed once on each subject.
No "intervention" as such.
For each individual participant, sample collection will be over a 28 day time period, following their usual infusion of Factor XIII.  This infusion takes approximately 5 minutes.</interventions>
    <comparator>There is no comparison/control group.</comparator>
    <control />
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the pharmacokinetics of FXIII in children and compare to literature based on adults. </outcome>
      <timepoint>Samples will be collected at eight specified time intervals, spread over 28 days.  Timing of samples has been adapted from recommended guidelines from the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.  Once all samples are collected for each individual, the data will used to determine the FXIII recovery and FXIII half-life.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To individualise and optomise treatment regimes in children.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Proven FXIII deficiencypatient registered in the Haemophilia program at the Royal Children's HospitalInformed consent obtainedpatients are receiving or have previously received Fibrogammin P as part of their treatment regime.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with haematocrit &lt;35%patients with platelet count &lt;100active bleeding at the time of testingpatient unable to cooperate with study procedures.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/02/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>4</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Clinical Haematology, Royal Children's Hospital, Parkville, Victoria</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Children's Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Barnes</name>
      <address>Department of Clinical Haematology
Royal Children's Hospital
Flemington Road
Parkville VIC 3052</address>
      <phone>+61 3 93455159</phone>
      <fax>+61 3 93491819</fax>
      <email>chris.barnes@rch.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Chris Barnes</name>
      <address>Department of Clinical Haematology
Royal Children's Hospital
Flemington Road
Parkville VIC 3052</address>
      <phone>+61 3 93455159</phone>
      <fax>+61 3 93491819</fax>
      <email>chris.barnes@rch.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>